• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.13% Nasdaq Up0.70%

    More On ASTM



    News & Info


    Analyst Coverage



    • Income Statement
    • Balance Sheet
    • Cash Flow

    Vericel Corporation (ASTM)

    2.77 0.00(0.00%) Nov 24, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Vericel Corporation
    64 Sidney Sreet
    Cambridge, MA 02139
    United States - Map
    Phone: 617-252-7999
    Fax: 617-252-7550
    Website: http://www.aastrom.com

    Index Membership:N/A
    Full Time Employees:150

    Business Summary 

    Aastrom Biosciences, Inc., a clinical-stage biotechnology company, focuses on the development of cell therapies for use in the treatment of severe chronic ischemic cardiovascular diseases. The company is developing a manufacturing technology platform, the Aastrom Replicell System, which enables the expansion of a various cell types, including the production of multicellular therapies expanded from an adult patientÂ’s own bone marrow that can be delivered directly to damaged tissues. Its lead product candidate include ixmyelocel-T, to treat patients with severe chronic ischemic cardiovascular diseases, such as advanced heart failure due to dilated cardiomyopathy, the third leading cause of heart failure, and critical limb ischemia. The company was founded in 1989 and is headquartered in Cambridge, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Vericel Corporation

    Key Executives 
    Mr. Dominick C. Colangelo Esq., 50
    Chief Exec. Officer, Pres, Treasurer and Director
    Mr. Daniel R. Orlando , 49
    Chief Operating Officer
    Dr. Sharon M. Watling PharmD, 50
    Mr. Gerard J. Michel MS, MBA, 51
    Chief Financial Officer, Principal Accounting Officer and VP of Corp. Devel.
    Dr. Ross Tubo Ph.D., 55
    Chief Scientific Officer
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders